Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors during the central anxious program, conolidine modulates alternate molecular targets. A Science Advances study found that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://yurir439qex7.jasperwiki.com/user